Valuation: Poxel

Market Cap 12.57M 14.31M 11.69M 10.73M 20.16M 1.38B 20.47M 139M 54.25M 678M 53.74M 52.58M 2.34B P/E 2023
-0.52x
P/E 2024 -0.36x
Enterprise Value 79.65M 90.69M 74.08M 67.98M 128M 8.73B 130M 880M 344M 4.29B 340M 333M 14.85B EV / Sales 2023
33.3x
EV / Sales 2024 11.2x
Free-Float
94.27%
Yield 2023 *
-
Yield 2024 -
1 day+0.50%
1 week+0.70%
Current month-1.23%
1 month-1.95%
3 months-24.72%
6 months-15.90%
Current year-14.10%
1 week 0.2
Extreme 0.195
0.21
1 month 0.19
Extreme 0.1942
0.21
Current year 0.19
Extreme 0.1942
0.48
1 year 0.19
Extreme 0.1942
0.58
3 years 0.12
Extreme 0.115
0.95
5 years 0.12
Extreme 0.115
6.84
10 years 0.12
Extreme 0.115
13.8
Manager TitleAgeSince
Chief Executive Officer 59 10/06/2026
Director of Finance/CFO - 01/12/2022
Corporate Officer/Principal - 01/05/2023
Director TitleAgeSince
Chairman - 31/07/2025
Director/Board Member - 31/07/2025
Director/Board Member - 31/07/2025
Date Insider Type Main position Quantity % Market Cap.
2/4/22 A Fiscal year

Founder

6,666 0.0232%
2/4/22 A Fiscal year

Founder

67,000 0.2334%
1/30/21 A Free

Founder

25,263 0.0888%
Change 5-day change 1-year change 3-year change Capi.($)
+0.50%+0.70%-66.44%-69.55% 12.3M
+0.93%+6.97%+62.83%+67.97% 57.28B
-1.92%+6.03%+43.68%+84.56% 54.99B
-0.46%-1.29%+3.28%+422.58% 23.18B
-2.97%-2.35%-22.03%-16.54% 22.59B
-0.36%+5.73%+30.99%-3.58% 20.46B
-1.34%+0.51%+25.02%-30.27% 17.56B
-1.44%+5.67%+32.54%+544.11% 15.67B
-1.30%-5.02%+165.62%+291.37% 14.46B
-0.50%-0.98%+23.62%+178.38% 13.92B
Average -0.89%+1.22%+29.91%+146.90% 24.01B
Weighted average by Cap. -0.87%+2.10%+41.17%+135.68%

Financials

2023 2024
Net sales 1.98M 2.26M 1.84M 1.69M 3.18M 217M 3.23M 21.88M 8.55M 107M 8.47M 8.28M 369M 6.64M 7.56M 6.17M 5.66M 10.64M 728M 10.8M 73.28M 28.63M 358M 28.36M 27.75M 1.24B
Net income -35.09M -39.95M -32.63M -29.94M -56.26M -3.85B -57.13M -388M -151M -1.89B -150M -147M -6.54B -18.3M -20.84M -17.02M -15.62M -29.35M -2.01B -29.8M -202M -78.98M -987M -78.24M -76.55M -3.41B
Net Debt 46.42M 52.86M 43.17M 39.62M 74.44M 5.09B 75.58M 513M 200M 2.5B 198M 194M 8.65B 67.08M 76.38M 62.38M 57.25M 108M 7.36B 109M 741M 289M 3.62B 287M 281M 12.5B
Logo Poxel
Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG® (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan.
Employees
5
Date Price Change Volume
24/07/26 €0.2010 +0.50% 47,539
23/07/26 €0.2000 +0.20% 118,197
22/07/26 €0.1996 +0.50% 41,598
21/07/26 €0.1986 -0.30% 198,738
20/07/26 €0.1992 -0.20% 88,732
  1. Stock Market
  2. Stocks
  3. POXEL Stock